June 5, 2024
Health Canada Approves Saladax’s 5-Fluorouracil Chemotherapy Therapeutic Drug Monitoring (TDM) Test
Bethlehem, PA – May 14, 2024 – Saladax Biomedical, Inc. (Saladax) is pleased to announce…
October 14, 2017
Saladax is Awarded “Best Poster Presentation” for Study on Individualized Dosing of Paclitaxel
Saladax Biomedical, Inc., recently presented a study on the value of adjusting paclitaxel doses. The…
October 19, 2016
Study Shows That Therapeutic Drug Monitoring Can Reduce Paclitaxel-Associated Neuropathy
Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic tests, today announced…
December 1, 2014
Saladax Biomedical Announces U.S. Launch of MyImatinib™ Chemotherapy Exposure Optimization Test
Commercial Launch of MyImatinib™ Test Expands MyCare™ portfolio of Chemotherapy Exposure Optimization tests available from…
July 23, 2014
Personalized Chemotherapy Tests Cleared for Use in China
Exposure Optimization Tests Fosun Diagnostics, a division of Fosun Pharmaceuticals, and Saladax Biomedical, Inc. today…
